Abstract:Senolytics are a class of drugs that selectively clear senescent cells (SC). The first senolytic drugs Dasatinib, Quercetin, Fisetin, and Navitoclax were discovered using a hypothesis‐driven approach. SC accumulate with aging and at causal sites of multiple chronic disorders, including diseases accounting for the bulk of morbidity, mortality, and health expenditures. The most deleterious SC are resistant to apoptosis and have up‐regulation of anti‐apoptotic pathways which defend SC against their own inflammatory senescence‐associated secretory phenotype (SASP), allowing them to survive, despite killing neighboring cells. Senolytics transiently disable these SCAPs, causing apoptosis of those SC with a tissue‐destructive SASP. Because SC take weeks to re‐accumulate, senolytics can be administered intermittently – a "hit‐and‐run" approach. In pre‐clinical models, senolytics delay, prevent, or alleviate frailty, cancers, and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, metabolic, and skin disorders as well as complications of organ transplantation, radiation, and cancer treatment. As anticipated for agents targeting the fundamental aging mechanisms that are "root cause" contributors to multiple disorders, potential uses of senolytics are protean, potentially alleviating over 40 conditions in preclinical studies, opening a new route for treating age‐related dysfunction and diseases. Early pilot trials of senolytics suggest they decrease senescent cells, reduce inflammation, and alleviate frailty in humans. Clinical trials for diabetes, idiopathic pulmonary fibrosis, Alzheimer's disease, COVID‐19, osteoarthritis, osteoporosis, eye diseases, and bone marrow transplant and childhood cancer survivors are underway or beginning. Until such studies are done, it is too early for senolytics to be used outside of clinical trials.

Death-seq identifies regulators of cell death and senolytic therapies

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis

Identification of senescence-related genes for potential therapeutic biomarkers of atrial fibrillation by bioinformatics, human histological validation, and molecular docking

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Development of novel flavonoid senolytics through phenotypic drug screening and drug design

An antibiotic that mediates immune destruction of senescent cancer cells

A large-scale CRISPR screen and identification of essential genes in cellular senescence bypass.

A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues

Discovery of senolytics using machine learning

Senolytics improve physical function and increase lifespan in old age

Dissecting Cell Death with Proteomic Scalpels

Functional genomic screens with death rate analyses reveal mechanisms of drug action

Developing transcriptomic signatures as a biomarker of cellular senescence

Identification of HSP90 inhibitors as a novel class of senolytics

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Connectivity Map and perturbation-based sensitivity analysis identifies MEK inhibitors as senolytics in human lung fibroblasts

Senolytic drugs: from discovery to translation

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

Guidelines for Regulated Cell Death Assays: A Systematic Summary, A Categorical Comparison, A Prospective